Affinity DataKi: 0.5nMAssay Description:Inhibition of dCK (unknown origin) by steady-state kinetic assayMore data for this Ligand-Target Pair
Affinity DataKi: 0.800nMAssay Description:Inhibition of dCK (unknown origin) by steady-state kinetic assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:Inhibition of dCK (unknown origin) by steady-state kinetic assayMore data for this Ligand-Target Pair
Affinity DataKi: 1.90nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 1.90nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 2.10nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 3.70nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 4.30nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 6nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 6.10nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 7.40nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 7.90nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 8nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 9.5nMAssay Description:Inhibition of dCK (unknown origin) by steady-state kinetic assayMore data for this Ligand-Target Pair
Affinity DataKi: 19nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 64nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 66nMAssay Description:Inhibition of human recombinant PAK1 kinase domain using coumarin/fluorescein-labeled FRET peptide as substrate preincubated for 10 mins followed by ...More data for this Ligand-Target Pair
Affinity DataKi: 400nMAssay Description:Displacement of 125I-MCP1 from human CCR2 receptor expressed in human HEK cell membraneMore data for this Ligand-Target Pair
Affinity DataIC50: 0.140nMAssay Description:Inhibition of matrix metalloproteinase-9, gelatinase-BMore data for this Ligand-Target Pair
Affinity DataIC50: 0.140nMAssay Description:Inhibition of matrix metalloproteinase-9, gelatinase-BMore data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMAssay Description:Inhibition of MMP-8 (matrix metalloproteinase-8)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.210nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.230nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:In vitro inhibitory activity against gelatinase-B(MMP-9).More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.330nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.330nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.420nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.430nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.440nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.540nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.570nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.570nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.610nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.630nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.660nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.790nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
Affinity DataIC50: 0.880nMAssay Description:Inhibitory activity against MMP-1 (Matrix metalloproteinase-1)More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair
TargetDisintegrin and metalloproteinase domain-containing protein 17(Homo sapiens (Human))
Astrazeneca
Curated by ChEMBL
Astrazeneca
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibitory activity against Tumor necrosis factor alpha-converting enzyme (TACE) in blood.More data for this Ligand-Target Pair